Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 5,310 matching trials from the live ClinicalTrials.gov search.

Filters: Louisville, Kentucky Clear all

Conditions: Rhinitis, Allergic, Seasonal
Interventions: AHIST NDC#58407-012-01; Drug
Lead sponsor: Magna Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Pregnancy, Sexually Transmitted Diseases
Interventions: Reducing the Risk, Love Notes; Behavioral
Lead sponsor: University of Louisville; Other
Eligibility: 14 Years to 19 Years
Enrollment: 1,450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 12
States / cities: Louisville, Kentucky

Conditions: Gastrointestinal Motility
Interventions: PillCam; Device
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Ipilimumab, Nivolumab, Paclitaxel, Positron Emission Tomography, Radiation Therapy; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 488
States / cities: Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 341 more

Conditions: Cardiovascular Disease, Diabetes Mellitus Type 2
Interventions: Placebo, aleglitazar; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years and older
Enrollment: 1,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 143
States / cities: Muscle Shoals, Alabama • Gilbert, Arizona • Phoenix, Arizona + 126 more

Conditions: Bacterial Infections
Interventions: Dalbavancin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Up to 28 Days
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: San Diego, California • Louisville, Kentucky • Kansas City, Missouri + 1 more

Conditions: Ulcerative Colitis (UC)
Interventions: XmAb942, Placebo; Biological · Drug
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 31
States / cities: Scottsdale, Arizona • Palo Alto, California • Bradenton, Florida + 25 more

Conditions: Multiple Myeloma
Interventions: Dexamethasone, Daratumumab, Bortezomib, Iberdomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 43
States / cities: Hot Springs, Arkansas • Cerritos, California • Fountain Valley, California + 38 more

Conditions: Cardiovascular Disease and Lipoprotein(a)
Interventions: Blood draw for Lp(a); Diagnostic Test
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 49,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 180
States / cities: Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 150 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 347
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more

Conditions: Distal and Lateral Subungual Onychomycosis
Interventions: Luliconazole Solution, 10%, Vehicle Solution; Drug
Lead sponsor: Topica Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 28
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more

Conditions: Dental Implants
Interventions: Dental Implant & ADM, Dental Implant & ADM & bone xenograft; Procedure
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Contraception, Bone Density
Interventions: Depo-Provera Contraceptive Injection - DP150CI; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2007
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • Torrance, California + 9 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Muraglitazar, Pioglitazone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 112
States / cities: Birmingham, Alabama • Columbiana, Alabama • Madison, Alabama + 109 more

Conditions: Rosacea
Interventions: Ivermectin 1% cream, Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules, Oral placebo capsules; Drug · Other
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Fort Smith, Arkansas • Sacramento, California • Boca Raton, Florida + 5 more

Conditions: Hormone Receptor Positive Breast Cancer
Interventions: Everolimus, Letrozole, Exemestane, Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study), Standard of care to treat stomatitis (Stomatitis sub-study); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Gilbert, Arizona • Loma Linda, California + 12 more

Conditions: Sarcoma
Interventions: dactinomycin, filgrastim, pegfilgrastim, sargramostim, cyclophosphamide, irinotecan hydrochloride, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 49 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 209
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Ovarian Cancer Recurrent
Interventions: Raludotatug Deruxtecan, Carboplatin, Paclitaxel, Bevacizumab, Rescue Medication, Pembrolizumab, Gemcitabine, Pegylated liposomal doxorubicin, MK-2010; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 10
States / cities: New Haven, Connecticut • Louisville, Kentucky • Shreveport, Louisiana + 7 more

Conditions: Prostate Cancer
Interventions: conventional surgery; Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Up to 75 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2010
U.S. locations: 61
States / cities: Anniston, Alabama • La Jolla, California • San Diego, California + 51 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,007 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 142
States / cities: Birmingham, Alabama • Mobile, Alabama • Sedona, Arizona + 128 more

Conditions: Heart Failure - NYHA II - IV
Interventions: CRT-D with a Quadripolar LV lead, CRT-D with INGEVITY+ pace/sense lead; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 43
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more

Conditions: Pneumonia
Interventions: Amoxicillin, Amoxicillin-clavulanate, Cefdinir, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 71 Months
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Louisville, Kentucky + 6 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Oral Treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more

Conditions: Plaque Psoriasis
Interventions: Calcipotriene/betamethasone; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Louisville, Kentucky

Search by objective public record fields.

Study of AHIST in Seasonal Allergic Rhinitis Patients

Louisville Teen Pregnancy Prevention Project

Clinical Evaluation Gastrointestinal Motility With PillCam

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis

The Clinical Effect of Implant Placement With a Simultaneous Soft Tissue Allograft

Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

Oracea Soolantra Association in Participants With Severe Rosacea

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

Surgery in Treating Patients With Prostate Cancer

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension

Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)